Glioblastoma cells (GBM)

Glioblastoma cells (GBM cells) represent a heterogeneous population of malignant brain tumor cells, and are not considered a single, conventional therapeutic target. Instead, glioblastoma is composed of multiple distinct cell types and subtypes, each potentially containing specific molecular markers that could serve as individual therapeutic targets. These include Glioblastoma stem cells (GSCs) with markers such as CD133, CD24, CD44, EGFR, PDGFRA, SOX2, and OCT4. Molecular subtypes within GBM include astrocyte-like (AC-like), oligodendrocyte progenitor-like (OPC-like), mesenchymal-like (MES-like), and neural progenitor-like (NPC-like) cells. The tumor microenvironment also contains stromal and immune cells like macrophages, microglia, T-cells, B-cells, and cancer-associated fibroblasts, which interact with glioblastoma cells. The designation of 'Glioblastoma cells' as a therapeutic target is incorrect, as it conflates a complex tumor cell population with a singular molecular entity.

Other names

GBM cells